HER2-Low Breast Cancer: Pathological and Clinical Landscape
2020 · Journal of Clinical Oncology · 776 citations
https://doi.org/10.1200/jco.19.02488
P
Paolo Tarantino
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
235
Papers
5.6K
Citations
34
h-index
88
i10-index
Paolo Tarantino is an academic researcher from Harvard University. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Advanced Breast Cancer Therapies & Breast Cancer Treatment Studies. The author has an h-index of 34, co-authored 200 publications.
ORCID: 0000-0001-8686-0228Papers by this author
worksInterstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates
2021 · JAMA Oncology · 146 citations
https://doi.org/10.1001/jamaoncol.2021.3595
Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons
2022 · Cancer Discovery · 66 citations
https://doi.org/10.1158/2159-8290.cd-22-0703
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
2023 · Nature Communications · 58 citations
https://doi.org/10.1038/s41467-023-43324-w
How I treat HER2-low advanced breast cancer
2023 · The Breast · 40 citations
https://doi.org/10.1016/j.breast.2023.01.005
Assessment of the HER2DX Assay in Patients With <i>ERBB2</i>-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab
2023 · JAMA Oncology · 34 citations
https://doi.org/10.1001/jamaoncol.2023.0181
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat